Shareholders' equity - Movements in AGA (Details)
|
|
|
|
|
|
|
|
|
|
|
|
12 Months Ended |
|
Dec. 15, 2025
EUR (€)
EquityInstruments
|
Sep. 30, 2025
EUR (€)
EquityInstruments
|
Sep. 26, 2025
EUR (€)
EquityInstruments
|
Jan. 17, 2025
EUR (€)
EquityInstruments
|
Jan. 06, 2025
EUR (€)
EquityInstruments
|
Dec. 13, 2024
EquityInstruments
|
Mar. 25, 2024
EquityInstruments
|
Mar. 25, 2024
shares
|
Dec. 15, 2023
EUR (€)
EquityInstruments
|
May 25, 2023
EUR (€)
EquityInstruments
|
Dec. 08, 2021
EUR (€)
EquityInstruments
|
Apr. 16, 2021
EUR (€)
EquityInstruments
|
Dec. 31, 2025
EquityInstruments
EUR (€)
|
Dec. 31, 2024
EquityInstruments
|
Dec. 31, 2024
EUR (€)
|
Dec. 31, 2023
EquityInstruments
|
Dec. 31, 2023
EUR (€)
|
Dec. 31, 2023
shares
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding, Beginning balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,410,814
|
|
790,600
|
|
|
| Issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,060,000
|
|
|
| Vested |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(363,000)
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(76,786)
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
1,410,814
|
|
|
| Bonus share award plans (AGA) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding, Beginning balance |
|
|
|
|
|
|
|
|
|
|
|
|
525,000
|
1,410,814
|
|
|
|
|
| Issued |
|
|
|
|
|
|
|
|
|
|
|
|
12,425,199
|
300,000
|
|
|
|
|
| Vested |
|
|
|
|
|
|
|
|
|
|
|
|
(907,756)
|
(1,074,013)
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
(5,093,932)
|
(111,801)
|
|
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
6,948,511
|
525,000
|
|
1,410,814
|
|
1,410,814
|
| Expense from share-based payment transactions | € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 3,293,000
|
|
€ 3,020,000
|
|
| AGA - Plan 2021 - 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
|
|
|
|
|
|
|
€ 11.3
|
|
|
|
|
|
|
| Outstanding, Beginning balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
297,599
|
|
340,800
|
|
|
| Issued |
|
|
|
|
|
|
|
|
|
|
|
466,000
|
|
|
|
|
|
|
| Vested |
|
|
|
|
|
|
|
|
|
|
|
|
|
(296,166)
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,433)
|
|
(43,201)
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
297,599
|
|
|
| AGA - Plan 2021 - 1 | Based on Non-Market Condition |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forfeited / Lapsed | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(13,719)
|
| AGA - Plan 2021 - 1 | Based on Market Condition |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forfeited / Lapsed | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(20,550)
|
| AGA - Plan 2021 - 1 | Departure of employees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forfeited / Lapsed | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8,932)
|
| AGA - Plan 2021 - 1 | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
|
|
|
|
|
|
|
€ 11.3
|
|
|
|
|
|
|
| AGA - Plan 2021 - 1 | Minimum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
|
|
|
|
|
|
|
€ 9.8
|
|
|
|
|
|
|
| AGA - Plan 2021 - bis |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
|
|
|
|
|
|
€ 12.2
|
|
|
|
|
|
|
|
| Outstanding, Beginning balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
65,215
|
|
76,800
|
|
|
| Issued |
|
|
|
|
|
|
|
|
|
|
123,000
|
|
|
|
|
|
|
|
| Vested |
|
|
|
|
|
|
|
|
|
|
|
|
|
(65,215)
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(11,585)
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
65,215
|
|
|
| AGA - Plan 2021 - bis | Based on Non-Market Condition |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forfeited / Lapsed | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,035)
|
| AGA - Plan 2021 - bis | Based on Market Condition |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forfeited / Lapsed | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4,550)
|
| AGA - Plan 2021 - bis | Departure of employees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forfeited / Lapsed | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4,000)
|
| AGA - Plan 2021 - bis | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
|
|
|
|
|
|
€ 12.2
|
|
|
|
|
|
|
|
| AGA - Plan 2021 - bis | Minimum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
|
|
|
|
|
|
11.4
|
|
|
|
|
|
|
|
| AGA 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
|
|
|
|
|
|
€ 4.18
|
|
|
|
|
|
|
|
| Outstanding, Beginning balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
373,000
|
|
|
| Vested |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(363,000)
|
|
(363,000)
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10,000)
|
|
|
| AGA 2022 | Departure of employees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forfeited / Lapsed | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10,000)
|
| AGA 2023-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
|
|
|
|
|
€ 2.6
|
|
|
|
|
|
|
|
|
| Outstanding, Beginning balance |
|
|
|
|
|
|
|
|
|
|
|
|
525,000
|
300,000
|
|
|
|
|
| Issued |
|
|
|
|
|
|
|
|
|
600,000
|
|
|
|
300,000
|
|
300,000
|
|
300,000
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
(139,294)
|
(75,000)
|
|
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
385,706
|
525,000
|
|
300,000
|
|
|
| AGA 2023-1 | Frederic Cren |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
|
|
|
|
|
300,000
|
|
|
|
|
|
|
300,000
|
|
|
|
|
| AGA 2023-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
|
|
|
|
€ 3.9
|
|
|
|
|
|
|
|
|
|
| Outstanding, Beginning balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
748,000
|
|
|
|
|
| Issued |
|
|
|
|
|
|
|
|
760,000
|
|
|
|
|
|
|
760,000
|
|
760,000
|
| Vested |
|
|
|
|
|
|
|
|
|
|
|
|
|
(712,632)
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
|
(35,368)
|
|
(12,000)
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
748,000
|
|
|
| AGA 2023-2 | Departure of employees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forfeited / Lapsed | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12,000)
|
| AGA 2024-1 (Tr1 - Tr2 - Tr3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
€ 2.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
|
|
|
800,000
|
|
|
|
|
|
|
|
800,000
|
|
|
|
|
|
| Vested |
|
|
|
|
|
|
|
|
|
|
|
|
(266,667)
|
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
(256,483)
|
|
|
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
276,850
|
|
|
|
|
|
| AGA 2024-1 (Tr1 - Tr2 - Tr3) | Frederic Cren |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
|
|
|
|
800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA 2024-2 (Tr1 - Tr2 - Tr3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
€ 2.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
|
|
|
800,000
|
|
|
|
|
|
|
|
800,000
|
|
|
|
|
|
| Vested |
|
|
|
|
|
|
|
|
|
|
|
|
(145,388)
|
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
(541,433)
|
|
|
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
113,179
|
|
|
|
|
|
| AGA 2024-3 (Tr1 - Tr2 - Tr3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
€ 2.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
|
|
|
1,577,000
|
1,577,000
|
|
|
|
|
|
|
1,577,000
|
|
|
|
|
|
| Vested |
|
|
|
|
|
|
|
|
|
|
|
|
(495,701)
|
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
(106,256)
|
|
|
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
975,043
|
|
|
|
|
|
| AGA 2024-4 (Tr1 - Tr2 - Tr3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
€ 2.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
|
|
113,000
|
|
113,000
|
|
|
|
|
|
|
113,000
|
|
|
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
113,000
|
|
|
|
|
|
| AGA 2025-1 (Tr1 - Tr2 - Tr3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
3,065,366
|
|
|
|
|
|
|
|
|
|
|
3,065,366
|
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
(1,476,703)
|
|
|
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
1,588,663
|
|
|
|
|
|
| AGA 2025-1 (Tr1 - Tr2 - Tr3) | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
€ 4.92
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA 2025-1 (Tr1 - Tr2 - Tr3) | Minimum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
€ 3.67
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA 2025-1 (Tr1 - Tr2 - Tr3) | Frederic Cren |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
6,158,699
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA 2025-1 (Tr4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
3,093,333
|
|
|
|
|
|
|
|
|
|
|
3,093,333
|
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
(2,463,263)
|
|
|
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
630,070
|
|
|
|
|
|
| AGA 2025-1 (Tr4) | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
€ 4.76
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA 2025-1 (Tr4) | Minimum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
€ 3.61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA 2025-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
€ 4.95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
|
2,370,500
|
|
|
|
|
|
|
|
|
|
2,370,500
|
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
(72,500)
|
|
|
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
2,298,000
|
|
|
|
|
|
| AGA 2025-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
€ 4.95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
|
38,000
|
|
|
|
|
|
|
|
|
|
38,000
|
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
|
|
|
|
|
|
(38,000)
|
|
|
|
|
|
| AGA 2025-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
€ 3.79
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
68,000
|
|
|
|
|
|
|
|
|
|
|
|
68,000
|
|
|
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
68,000
|
|
|
|
|
|
| AGA 2025-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
€ 3.79
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
500,000
|
|
|
|
|
|
|
|
|
|
|
|
500,000
|
|
|
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
500,000
|
|
|
|
|
|
| PAGUP 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per instrument at grant date | € |
|
|
|
|
|
|
|
|
|
€ 2.6
|
|
|
|
|
|
|
|
|
| Outstanding, Beginning balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
300,000
|
|
|
|
|
| Issued |
|
|
|
|
|
|
|
|
|
300,000
|
|
|
|
|
|
300,000
|
|
|
| Outstanding, Ending balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
300,000
|
|
|
| Expense from share-based payment transactions | € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 50,000
|
|
€ 122,000
|
|
| PAGUP 2023 | Frederic Cren |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shareholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issued |
|
|
|
|
|
|
|
300,000
|
|
300,000
|
|
|
|
|
|
|
|
|
| Forfeited / Lapsed |
|
|
|
|
|
|
(300,000)
|
(300,000)
|
|
|
|
|
|
(300,000)
|
|
|
|
|